IL-13 Contributes to Drug Resistance of NK/T-Cell Lymphoma Cells by Regulating ABCC4

Ni, Mingli; Qin, Beibei; Xie, Ling; Zhang, Xudong; Yang, Jiezhi; Lv, Hongqiong; Yang, Mingyue; Zhang, Mingzhi

doi:10.1155/2018/2606834

Cited by 8 publications

(4 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Secretion of IL-4 and IL-10 by cancer cells has been shown to confer drug-induced resistance, by specifically inhibiting apoptotic pathways (87)(88)(89). IL-13 has also been shown to promote drug resistance in lymphoma, although the mechanism is unclear (90). These cytokines can thus be useful as predictive biomarkers, and to monitor resistance towards anticancer drugs.…”

Section: Cytokines Induced Due To Therapy and Resistance To Therapymentioning

confidence: 99%

Tumor-Induced Inflammatory Cytokines and the Emerging Diagnostic Devices for Cancer Detection and Prognosis

et al. 2021

View full text Add to dashboard Cite

Chronic inflammation generated by the tumor microenvironment is known to drive cancer initiation, proliferation, progression, metastasis, and therapeutic resistance. The tumor microenvironment promotes the secretion of diverse cytokines, in different types and stages of cancers. These cytokines may inhibit tumor development but alternatively may contribute to chronic inflammation that supports tumor growth in both autocrine and paracrine manners and have been linked to poor cancer outcomes. Such distinct sets of cytokines from the tumor microenvironment can be detected in the circulation and are thus potentially useful as biomarkers to detect cancers, predict disease outcomes and manage therapeutic choices. Indeed, analyses of circulating cytokines in combination with cancer-specific biomarkers have been proposed to simplify and improve cancer detection and prognosis, especially from minimally-invasive liquid biopsies, such as blood. Additionally, the cytokine signaling signatures of the peripheral immune cells, even from patients with localized tumors, are recently found altered in cancer, and may also prove applicable as cancer biomarkers. Here we review cytokines induced by the tumor microenvironment, their roles in various stages of cancer development, and their potential use in diagnostics and prognostics. We further discuss the established and emerging diagnostic approaches that can be used to detect cancers from liquid biopsies, and additionally the technological advancement required for their use in clinical settings.

show abstract

Section: Cytokines Induced Due To Therapy and Resistance To Therapymentioning

confidence: 99%

Tumor-Induced Inflammatory Cytokines and the Emerging Diagnostic Devices for Cancer Detection and Prognosis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Response rates of MDR1 -negative subjects to CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) is significantly higher than those MDR1 -positive in 1 study but not others [ 90 ]. Interleukin-13 (IL-13) and ABCC4 are highly expressed in NKTLs and also contributes to doxorubicin resistance [ 91 ]. Wang et al reported a higher concentration of IL-2 receptors α (IL-2R α) on NKTL cell lines compared with normal NK-cells [ 92 ].…”

Section: What Is the Mechanism Of Multi-drug Resistance (Mdr) In Nktl?mentioning

confidence: 99%

NK-/T-cell lymphomas

Wang

Gale

et al. 2021

Leukemia

View full text Add to dashboard Cite

Natural killer/T-cell lymphoma (NKTL) is a sub-type of Epstein–Barr virus (EBV)-related non-Hodgkin lymphomas common in Asia and Latin America but rare elsewhere. Its pathogenesis is complex and incompletely understood. Lymphoma cells are transformed from NK- or T-cells, sometimes both. EBV-infection and subsequent genetic alterations in infected cells are central to NKTL development. Hemophagocytic syndrome is a common complication. Accurate staging is important to predict outcomes but there is controversy which system is best. More than two-thirds of NKTL lympohmas are localized at diagnosis, are frequently treated with radiation therapy only and have 5-year survival of about 70 percent. Persons with advanced NKTLs receive radiation therapy synchronously or metachronously with diverse multi-drug chemotherapy typically including l-asparginase with 5-year survival of about 40 percent. Some persons with widespread NKTL receive chemotherapy only. There are few data on safety and efficacy of high-dose therapy and a haematopoietic cell autotransplant. Immune therapies, histone deacetylase (HDAC)-inhibitors and other drugs are in early clinical trials. There are few randomized controlled clinical trials in NKTLs and no therapy strategy is clearly best; more effective therapy(ies) are needed. Some consensus recommendations are not convincingly evidence-based. Mechanisms of multi-drug resistance are considered. We discuss these issues including recent advances in our understanding of and therapy of NKTLs.

show abstract

“…Based on gene expression regulation technology, overexpression of ABCC4 and ABCG4 can induce epirubicin (EPI) and cisplatin (DDP) resistance in human NK/ T cell lymphoma YTS cells and reduce cell apoptosis [ 72 ]. Meanwhile,IL-6, IL-10, and IL13 mediate ABCC4 resistance in T-cell lymphoma [ 64 , 73 , 74 ].…”

Section: Introductionmentioning

confidence: 99%

Therapeutic challenges in peripheral T-cell lymphoma

Luan,

Li,

Luan

et al. 2024

Mol Cancer

View full text Add to dashboard Cite

Peripheral T-cell lymphoma (PTCL) is a rare and heterogeneous group of hematological malignancies. Compared to our knowledge of B-cell tumors, our understanding of T-cell leukemia and lymphoma remains less advanced, and a significant number of patients are diagnosed with advanced stages of the disease. Unfortunately, the development of drug resistance in tumors leads to relapsed or refractory peripheral T-Cell Lymphomas (r/r PTCL), resulting in highly unsatisfactory treatment outcomes for these patients. This review provides an overview of potential mechanisms contributing to PTCL treatment resistance, encompassing aspects such as tumor heterogeneity, tumor microenvironment, and abnormal signaling pathways in PTCL development. The existing drugs aimed at overcoming PTCL resistance and their potential resistance mechanisms are also discussed. Furthermore, a summary of ongoing clinical trials related to PTCL is presented, with the aim of aiding clinicians in making informed treatment decisions.

show abstract

IL-13 Contributes to Drug Resistance of NK/T-Cell Lymphoma Cells by Regulating ABCC4

Cited by 8 publications

References 34 publications

Tumor-Induced Inflammatory Cytokines and the Emerging Diagnostic Devices for Cancer Detection and Prognosis

Tumor-Induced Inflammatory Cytokines and the Emerging Diagnostic Devices for Cancer Detection and Prognosis

NK-/T-cell lymphomas

Therapeutic challenges in peripheral T-cell lymphoma

Contact Info

Product

Resources

About